Health state utilities associated with hyperphagia: Data for use in cost-utility models
- PMID: 37546284
- PMCID: PMC10399521
- DOI: 10.1002/osp4.652
Health state utilities associated with hyperphagia: Data for use in cost-utility models
Abstract
Objective: Rare genetic diseases of obesity typically present with hyperphagia, a pathologic desire to consume food. Cost-utility models assessing the value of treatments for these rare diseases will require health state utilities representing hyperphagia. This study estimated utilities associated with various hyperphagia severity levels.
Methods: Four health state vignettes were developed using published literature and clinician input to represent various severity levels of hyperphagia. Utilities were estimated for these health states in a time trade-off elicitation study in a UK general population sample.
Results: In total, 215 participants completed interviews (39.5% male; mean age 39.1 years). Mean (SD) utilities were 0.98 (0.02) for no hyperphagia, 0.91 (0.10) for mild hyperphagia, 0.70 (0.30) for moderate hyperphagia, and 0.22 (0.59) for severe hyperphagia. Mean (SD) disutilities were -0.08 (0.10) for mild, -0.28 (0.30) for moderate, and -0.77 (0.58) for severe hyperphagia.
Conclusions: These data show increasing severity of hyperphagia is associated with decreased utility. Utilities associated with severe hyperphagia are similar to those of other health conditions severely impacting quality of life (QoL). These findings highlight that treatments addressing substantial QoL impacts of severe hyperphagia are needed. Utilities estimated here may be useful in cost-utility models of treatments for rare genetic diseases of obesity.
Keywords: health state utilities; hyperphagia; obesity; time trade‐off.
© 2022 Rhythm Pharmaceuticals, Inc. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.
Conflict of interest statement
Louis S. Matza and Timothy A. Howell are employed by Evidera, a company that received funding from Rhythm Pharmaceuticals, Inc., for time spent on this research. Ethan Lazarus received payment or honoraria for lectures, speaker bureaus, advisory boards or educational events for Novo Nordisk, Currax Pharmaceuticals, Nestle Health Services, and the Obesity Medicine Association; and serves as president of the Obesity Medicine Association and a delegate of the American Medical Association. Usha G. Mallya is an employee of Rhythm Pharmaceuticals, Inc. As an employee, they receive stocks or stock options. Anthony P. Goldstone has been principal investigator for clinical trials sponsored by Rhythm Pharmaceuticals, Inc.; a member of the Data Safety and Monitoring Board for clinical trials for and received speaker honorarium from Novo Nordisk; and a consultant or member of medical advisory board for Millendo Therapeutics, Soleno Therapeutics, Helsinn Healthcare S.A., Evidera, Rhythm Pharmaceuticals, Inc., and Radius Health. W. Scott Butsch has served as a consultant or member of clinical and education advisory boards for Novo Nordisk; Rhythm Pharmaceuticals, Inc.; and Merck.
Figures

References
LinkOut - more resources
Full Text Sources